Nadim Ahmed
President, CEO & DirectorMr. Nadim Ahmed, M.S., Independent is Director of Disc Medicine, Inc. from July 2025. Mr. Ahmed has been a President, Chief Executive Officer and Director of Cullinan Therapeutics, Inc. (formerly known as Cullinan Oncology, Inc.) since October 18, 2021. He joined Cullinan Therapeutics, Inc. (formerly known as Cullinan Oncology, Inc.) in October 2021. He has been Executive Director at Cullinan Mica Corp. He had been the President of Global Hematology and Oncology at Celgene Corporation since November 2018. Mr. Ahmed had been President of Hematology at Bristol-Myers Squibb Company since November 2019 until January 2021 and served as its Executive Vice President since December 2019 until January 2021. He served as President of Hematology and Oncology at Celgene Corporation since August 23, 2017 until November 2018. Mr. Ahmed served as President of Worldwide Markets, Hematology and Oncology at Celgene Corporation since March 2016 and its General Manager of US Hematology & Oncology from August 2014 to March 2016. He joined the Global Marketing team in 2010 as Global Head of Marketing for Celgene's Myeloma Franchise after holding positions of increasing responsibility in Clinical Development, Medical Affairs, Global and US Marketing at GSK. He holds a Bachelor of Science Degree in Pharmacology from University College London, UK and a Master of Science Degree in Information Technology from Loughborough University, UK.
Positions
- Company NameCullinan Therapeutics, Inc.Stock CodeCGEMPositionPresident, CEO & DirectorColleagues
- AAAnthony A. RosenbergIndependent Chairman of the Board
- MKMary Kay FentonChief Financial Officer
- JJJeffrey JonesChief Medical Officer
- PAPatrick A. BaeuerleCo-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board
- JMJennifer MichaelsonChief Scientific Officer
- SWStephen W. WebsterIndependent Director
- DDDavid D. MeekIndependent Director
